Clinical trial • Phase IV • Infectious Disease

ERYTHROMYCIN for Surgical site infection

Phase IV trial of ERYTHROMYCIN for Surgical site infection. Randomised. 322 participants.

Overview

Trial Therapeutic Area
Infectious Disease
Trial Disease
Surgical site infection
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
28-01-2025
First CTIS Authorization Date
30-01-2025

Trial design

Randomised Phase IV trial across 1 site in Ireland.

Randomised
Yes
Target Sample Size
322

Eligibility

Recruits 322 Vulnerable population not selected; trial enrols adults (≥ 18 years). Inability to provide informed consent is listed as an exclusion criterion..

Pregnancy Exclusion
(9) Patients who have a positive pregnancy test.
Vulnerable Population
Vulnerable population not selected; trial enrols adults (≥ 18 years). Inability to provide informed consent is listed as an exclusion criterion.

Inclusion criteria

  • {"criterion_text":"- Adult patients (aged ≥ 18 years) scheduled for elective laparoscopic, open and/or robotic assisted colon or rectal surgery for benign or malignant disease"}

Exclusion criteria

  • {"criterion_text":"- 1) inability to provide informed consent"}
  • {"criterion_text":"- (2) acute surgery for bleeding, perforation or obstruction"}
  • {"criterion_text":"- (3) uncontrolled diabetes mellitus"}
  • {"criterion_text":"- (4) preoperative steroid use"}
  • {"criterion_text":"- (5) antibiotic use within 2 weeks of proposed elective surgery date"}
  • {"criterion_text":"- and (6) previous allergic reaction to the antibiotics utilised in this study."}
  • {"criterion_text":"- (7) Patients with contraindications to neomycin and erythromycin."}
  • {"criterion_text":"- (8) Patients with renal and hepatic impairment."}
  • {"criterion_text":"- (9) Patients who have a positive pregnancy test."}
  • {"criterion_text":"- (10) Patients requiring more extensive antibiotic prophylaxis."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Incidence of surgical site infection","definition_or_measurement_approach":""}

Secondary endpoints

  • {"endpoint_text":"- Infectious complications other than surgical site infections","definition_or_measurement_approach":""}
  • {"endpoint_text":"- length of hospital stay","definition_or_measurement_approach":""}
  • {"endpoint_text":"- postoperative complications as per Clavien Dindo Classification","definition_or_measurement_approach":""}
  • {"endpoint_text":"- anastomotic leakage","definition_or_measurement_approach":""}
  • {"endpoint_text":"- mortality","definition_or_measurement_approach":""}

Recruitment

Planned Sample Size
322
Recruitment Window Months
101
Consent Approach
Informed consent required; inability to provide informed consent is listed as an exclusion. A subject information and informed consent form document (SELDDEC Consent) is listed in the trial documents.

Geography

Total Number Of Sites
1
Total Number Of Participants
322

Ireland

Earliest CTIS Part Ii Submission Date
19-01-2025
Latest Decision Or Authorization Date
07-05-2025
Processing Time Days
108
Number Of Sites
1
Number Of Participants
322

Sites

Site Name
University Hospital Limerick
Department Name
General and Colorectal Surgery
Principal Investigator Name
Colin Peirce
Principal Investigator Email
colinpeirce@rcsi.ie
Contact Person Name
Colin Peirce
Contact Person Email
colinpeirce@rcsi.ie
Number Of Participants
322

Sponsor

Primary sponsor

Full Name
University Hospital Limerick
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Ireland

Investigational products

Investigational Product Name
Erythromycin Tablets BP 250mg
Active Substance
ERYTHROMYCIN
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Marketing authorisation PL 40147/0036
Maximum Dose
1 g
Investigational Product Name
Neomycin 500mg Tablets
Active Substance
NEOMYCIN SULPHATE PH. EUR.
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Marketing authorisation PL 20072/0223
Maximum Dose
1 g
Combination Treatment
Yes

Related trials

Other published trials that may interest you.